Nurix Therapeutics, a Celgene-backed cancer treatment developer based on UC Berkeley and San Francisco research, priced shares above its range to raise $209m.

Nurix Therapeutics, a US-based oncology therapy developer based on research at University of California (UC), Berkeley and UC San Francisco, priced its shares at $19 on Thursday and raised $209m when it went public on Friday.
The company issued 11 million shares on the Nasdaq Global Market and is trading under the ticker symbol NRIX. Nurix had initially planned to sell 8.8 million shares priced at $16 to $18.
Founded in 2009 as Kura Therapeutics, Nurix is…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in